Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Biomx Inc.

Headquarters: Ness Ziona, Israel
Year Founded: 2015
Status: Public
Industry Sector: HealthTechnology
CEO: Jonathan Eithan Solomon, MBA
Number Of Employees: 57
Enterprise Value: $19,190,365
PE Ratio: -0.16
Exchange/Ticker 1: NYSE:PHGE
Exchange/Ticker 2: N/A
Latest Market Cap: $15,722,500

BioCentury | Mar 9, 2024
Finance

Public equity report: Boundless to test IPO appetite as follow-ons continue to deliver

Public offerings by Akero, BridgeBio, RegenxBio, Apogee, plus PIPEs for Ventyx and BiomX-Adaptive Phage union
BioCentury | Sep 8, 2023
Management Tracks

Greig named non-executive chair at Nucleome

Plus: updates from SparX, Breathe, Find and MedinCell
BioCentury | Jun 10, 2023
Discovery & Translation

Bacteriophage therapy for liver dysfunction; plus Genentech’s pan-TEAD inhibitor and more

BioCentury’s roundup of translational news
BioCentury | Feb 9, 2023
Management Tracks

Bill Anderson becomes CEO of Bayer

Plus: High leaving AskBio, and updates from Verily, PhRMA, MOMA and more 
BioCentury | May 25, 2022
Finance

May 24 Quick Takes: Duke Street Bio debuts to develop PARP inhibitors

Plus Alvotech’s Stelara biosimilar demonstrates bioequivalence and updates from uniQure, CSL, Alpine and more
BioCentury | Jan 8, 2022
Product Development

Phagelux: new life in lysins

CEO Mark Engel narrows the focus of his cross-border biotech to first- and best-in-class skin products and phage-based platform technologies. 
Items per page:
1 - 10 of 23